Cargando…
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice
BACKGROUND: Since its first appearance in the USA in 1999, West Nile virus (WNV) has spread in the Western hemisphere and continues to represent an important public health concern. In the absence of effective treatment, there is a medical need for the development of a safe and efficient vaccine. Liv...
Autores principales: | Spohn, Gunther, Jennings, Gary T, Martina, Byron EE, Keller, Iris, Beck, Markus, Pumpens, Paul, Osterhaus, Albert DME, Bachmann, Martin F |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914671/ https://www.ncbi.nlm.nih.gov/pubmed/20604940 http://dx.doi.org/10.1186/1743-422X-7-146 |
Ejemplares similares
-
Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus
por: Martina, Byron E., et al.
Publicado: (2008) -
West Nile Virus: Immunity and Pathogenesis
por: Lim, Stephanie M., et al.
Publicado: (2011) -
A Recombinant Influenza A Virus Expressing Domain III of West Nile Virus Induces Protective Immune Responses against Influenza and West Nile Virus
por: Martina, Byron E. E., et al.
Publicado: (2011) -
Susceptibility of Carrion Crows to Experimental Infection with Lineage 1 and 2 West Nile Viruses
por: Lim, Stephanie M., et al.
Publicado: (2015) -
In Vitro and in Vivo Evaluation of Mutations in the NS Region of Lineage 2 West Nile Virus Associated with Neuroinvasiveness in a Mammalian Model
por: Szentpáli-Gavallér, Katalin, et al.
Publicado: (2016)